Golidocitinib (NCT06630091)

Name: Golidocitinib trial for Peripheral T Cell Lymphoma (NCT06630091)
Uploaded: 2026-10-31T07:15:48.780Z
Duration: 1 min 19 s
Description: Golidocitinib trial for Peripheral T Cell Lymphoma (NCT06630091). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06630091.

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study: a one-minute explainerNCT066300911 min

Golidocitinib trial for Peripheral T Cell Lymphoma (NCT06630091). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with untreated peripheral T-cell lymphoma of four types: not otherwise specified, angioimmunoblastic, follicular T-cell, or T-follicular-helper phenotype. Transplant-eligible and transplant-ineligible patients can enter.

The idea: test oral golidocitinib alone or with CHOP chemotherapy. Golidocitinib blocks JAK1 signaling that can support cancer-cell growth. Its dosing differs when combined with CHOP. Researchers assess safety and cancer control, using scans and samples. The record does not explain how patients move between single-drug and combination treatment.

This phase 2 study plans 30 patients. Luis Malpica Castillo leads MD Anderson's recruiting Houston site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.